Phase 2a Study of Epcoritamab Before and After CAR-T Cell Therapy for Relapsed or Refractory Large B-cell Lymphomas

What this Trial Is About

Researchers are evaluating the use of epcoritamab treatment before and after CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphomas. The study aims to see if epcoritamab can be given safely before CAR T-cell infusion and if it can help treat any remaining lymphoma after CAR T-cell therapy. This is a phase 2a clinical trial sponsored by the Abramson Cancer Center at Penn Medicine. Participants will receive epcoritamab as a bridging therapy during the first three cycles on days 1, 8, 15, and 22. The dosing starts with a low priming dose of 0.16 mg subcutaneously on day 1, an intermediate dose of 0.8 mg on day 8, and full doses of 48 mg from day 15 onward. After CAR T-cell infusion, some participants may continue to receive epcoritamab for up to 12 cycles to address residual lymphoma. During the study, participants will be monitored from the start of epcoritamab through CAR T-cell infusion and follow-up, including assessments of side effects and response to treatment. Researchers will measure outcomes such as successful CAR T-cell infusion after epcoritamab treatment, response rates after two cycles of epcoritamab, safety through adverse event tracking, and survival outcomes up to five years. Imaging scans, laboratory tests, and clinical evaluations will be used to track lymphoma status and treatment effects throughout the study period.

Epcoritamab-CAR T Cells for Large B-cell Lymphomas